Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial

Mats Jerkeman, Karin Fahl Wader, Ingrid Glimelius, Annika Pasanen, Won Seog Kim, Louise Krüger Hansen, Jon Riise, Martin Hutchings, Hashim Hussein Elhussein, Carsten Utoft Niemann, Rasmus Rask Kragh Jørgensen, Tarec Christoffer El-Galaly, Mats Ehinger, Klaus Beiske, Rose-Marie Amini, Michael Boe Møller, Marja-Liisa Karjalainen-Lindsberg, Jacob Haaber Christensen

Blood (2024) 144 (Supplement 1): 747.

https://doi.org/10.1182/blood-2024-192939

Published: 2024

Journal Articles

Unraveling the Role and Spatial Architecture of Cancer-Associated Fibroblasts in Classical Hodgkin Lymphoma

Suvi-Katri Leivonen, Kristiina Karihtala, Marja-Liisa Karjalainen-Lindsberg, Teijo Pellinen, Sirpa Leppä

Blood (2023) 142 (Supplement 1): 4386.

https://doi.org/10.1182/blood-2023-173117

Published: 2023

Journal Articles

Clinical Impact of the Spatial Organization of the Immune Tumor Microenvironment in Diffuse Large B-Cell Lymphoma

Matias Autio, Suvi-Katri Leivonen, Marja-Liisa Karjalainen-Lindsberg, Teijo Pellinen, Sirpa Leppä

Blood (2023) 142 (Supplement 1): 178.

https://doi.org/10.1182/blood-2023-177893

Published: 2023

Journal Articles

Unraveling the Transcriptional Landscape of Nodular Lymphocyte-Predominant Hodgkin Lymphoma and T-Cell/Histiocyte Rich Large B-Cell Lymphoma: Impact of Tumor Microenvironment and Checkpoint Gene Expression

Blood (2023) 142 (Supplement 1): 176.

https://doi.org/10.1182/blood-2023-182294

Published: 2023

Journal Articles

Distinct Genetic and Fragmentomic Signatures of Plasma Ctdna Synergize and Resolve Clinical Challenges in Patients with Large B-Cell Lymphoma

Leo Meriranta, Maare Arffman, Judit Mészáros Jørgensen, Harald Holte, Kristina Drott, Henrikki Almusa, Emma Saarinen, Sari Hannula, Marja-Liisa Karjalainen-Lindsberg, Klaus Beiske, Mette Ølgod Pedersen, Øystein Fluge, Peter de Nully Brown, Sirkku Jyrkkiö, Sirpa Leppä

Blood (2023) 142 (Supplement 1): 1625.

https://doi.org/10.1182/blood-2023-188493

Published: 2023

Journal Articles

Extranodal Marginal Zone Lymphomas Show Recurrent Mutations in DNA Repair Genes, Cancer-Associated Proliferative Signaling and NOTCH1 Signaling Pathways, Regardless of Anatomic Site

Blood (2022) 140 (Supplement 1): 6378–6380.

https://doi.org/10.1182/blood-2022-165616

Published: 2022

Journal Articles

Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53- wild Type Mantle Cell Lymphoma

Blood (2022) 140 (Supplement 1): 3500–3503.

https://doi.org/10.1182/blood-2022-168002

Published: 2022

Journal Articles

The Composition, Cell Interaction Patterns and Prognostic Impact of the Tumor Microenvironment in Germinal Center B-Cell and Activated B-Cell-like Diffuse Large B-Cell Lymphoma

Matias Autio, Suvi-Katri Leivonen, Oscar Brück, Marja-Liisa Karjalainen-Lindsberg, Teijo Pellinen, Sirpa Leppa

Blood (2022) 140 (Supplement 1): 3568–3569.

https://doi.org/10.1182/blood-2022-158431

Published: 2022

Journal Articles

Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome

Blood (2022) 140 (Supplement 1): 3559–3561.

https://doi.org/10.1182/blood-2022-169476

Published: 2022

Journal Articles

Oncogenic Mutational Disruption of KLHL6 Dimers Fuels B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma

Leo Meriranta, Selma Sorri, Sadia Zafar, Xiaonan Liu, Eerika Sahlberg, Olli Dufva, Helka Göös, Marja-Liisa Karjalainen-Lindsberg, Markku Varjosalo, Marko Hyytiäinen, Sirpa Leppa

Blood (2022) 140 (Supplement 1): 5889–5890.

https://doi.org/10.1182/blood-2022-166768

Published: 2022

Journal Articles

Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study

Blood (2022) 140 (Supplement 1): 1768–1769.

https://doi.org/10.1182/blood-2022-158183

Published: 2022

Journal Articles

Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma

Blood (2022) 139 (12): 1863–1877.

https://doi.org/10.1182/blood.2021012852

Published: 2022

Includes: Supplemental data

Journal Articles

Protein Profiling Identify Distinct Tumor-Tissue Protein Expression Pattern Specific for Relapsing Diffuse Large B-Cell Lymphoma

Maja Ludvigsen, Diani Wilken, Marja-Liisa Karjalainen-Lindsberg, Klaus Beiske, Lars Pedersen, Jan Delabie, Francesco d'Amore, Harald Holte, Sirpa Leppa, Judit Jørgensen, Bent Honoré

Blood (2021) 138 (Supplement 1): 4499.

https://doi.org/10.1182/blood-2021-145690

Published: 2021

Journal Articles

ALK-Negative Anaplastic Large Cell Lymphomas Encompass Distinct Subgroups Including an ALK-Positive-like Subgroup with Favorable Prognosis

Blood (2021) 138 (Supplement 1): 2403.

https://doi.org/10.1182/blood-2021-148807

Published: 2021

Journal Articles

Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma

Xiang Li, Rachel Kositsky, Anupama Reddy, PhD, Cassandra Love, Kikkeri Naresh, Jean L. Koff, MD, Ilja Nystrand, Sirpa Leppä, MD PhD, Annika Pasanen, MD PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Johannes Dunkel, Panu Kovanen, MD PhD, Qiu Qin, Govind Bhagat, MD, Rebecca J Leeman-Neill, MDPhD, Rashmi S. Goswami, MD PhD, Sarah Wildeman, Jan Delabie, MDPhD, Richard Burack, MD PhD, Andrew G Evans, MD PhD, Catalina Amador, MD, Ji Yuan, Hina Naushad Qureishi, Shaoying Li, MD, Jie Xu, C. Cameron Yin, MD PhD, Anne Ortved Gang, Peter H. Norgaard, MDPhD, Mette Ø Pedersen, MD, Jason Yongsheng Chan, MBBS, MRCP, Daryl Ming Zhe Cheah, Shin Yeu Ong, MD FRCPath, Chee Leong Cheng, FRCPA, FRCPath, MBBS, Lianne Lee, Felik Paulua, Sarah L. Ondrejka, DO, Eric D. Hsi, MD, Magdalena Czader, MD PhD, Lin Wang, PhD, Amber Landis, Michael C. Churnetski, David L. Jaye, MD, Christopher R. Flowers, MD MS, Chad M. McCall, MD PhD, Jadee Neff, MD PhD, Matthew S. McKinney, MD, Yuri Fedoriw, Eric Powers, Nathan D Montgomery, MD, Agata M. Bogusz, MDPhD, Andrea Stafford Hintz, HSLT, Alexandra E. Kovach, MD, Nishitha Reddy, MD, Mary Ann Thompson Arildsen, MD PhD, Emily F Mason, MD PhD, Ridas Juskevicius, MD, William Choi, MBBS,MRCP, Rex Au-Yeung, Eric Tse, MBBS, PhD FRCP, FRCPath, Vincent Sarno, Amy Chadburn, MD, Rafael Lopez, MD, Jennifer R Chapman, MD, Amir Behdad, MD, Neta Goldschmidt, MD, John Goodlad, MD, Cathy Burton, Raju Pillai, MD, Abner Louissaint, Jr., MD PhD, Dina Sameh Soliman, MD MB, MMSc, Razvan Panea, Tushar Dave, Barbara Xiong, Eileen Smith, Sandeep Dave, MD

Blood (2019) 134 (Supplement_1): 19.

https://doi.org/10.1182/blood-2019-130255

Published: 2019

Journal Articles

The DLBCL90 Double-Hit Gene Expression Signature Is Not Associated with Inferior Survival in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma Treated with Dose-Intensive Immunochemotherapy

Kathrine T. Isaksen, MD, Klaus Beiske, MD PhD, Erlend B. Smeland, MD PhD, Judit Jørgensen, MD PhD, Marianne Brodtkorb, MD PhD, June Helen Myklebust, PhD, Mats Jerkeman, MD Professor, Leo Meriranta, MD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Sirpa Leppa, MD PhD, David W. Scott, MBChB, PhD, Harald Holte, MD PhD, Yngvild Nuvin Blaker, MD PhD

Blood (2019) 134 (Supplement_1): 1485.

https://doi.org/10.1182/blood-2019-121467

Published: 2019

Journal Articles

Molecular Background of Double Protein Expressor B-Cell Lymphomas

Leo Meriranta, MD, Amjad Alkodsi, PhD, Annika Pasanen, MD PhD, Jari Haukka, PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Sirpa Leppa, MD Prof

Blood (2019) 134 (Supplement_1): 2781.

https://doi.org/10.1182/blood-2019-131220

Published: 2019

Journal Articles

Molecular Profiling of Aggressive Non-Hodgkin Lymphoma - Results from a Phase 1/2 Preben Study

Suvi-Katri Leivonen, PhD, Judit Jørgensen, MD PhD, Thomas Stauffer Larsen, MD PhD, Annika Pasanen, MD PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Helle M Toldbod, PhD, Francesco d'Amore, MD PhD, Sirpa Leppa, MD PhD

Blood (2019) 134 (Supplement_1): 5314.

https://doi.org/10.1182/blood-2019-129113

Published: 2019

Journal Articles

Tumor Microenvironment Differs between Germinal Centre B-Cell and Non-Germinal Centre B-Cell like Diffuse Large B-Cell Lymphomas and Has Subtype-Specific Prognostic Impact on Survival

Matias Autio, Suvi-Katri Leivonen, PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Teijo Pellinen, PhD, Sirpa Leppa, MD PhD

Blood (2019) 134 (Supplement_1): 5230.

https://doi.org/10.1182/blood-2019-129681

Published: 2019

Journal Articles

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Francesco d'Amore, MD, Sirpa Leppä, MD, Maria Gomes da Silva, MD PhD, Thomas Relander, Grete Fossum Lauritzsen, Peter De Nully Brown, Antonio Pezzutto, Jeanette K. Doorduijn, MD PhD, Eckhart Weidmann, Michel van Gelder, Achiel Van Hoof, Ilse Christiansen, Unn Merete Fagerli, MD PhD, Hans Hagberg, MD, P.J. Lugtenburg, Jan Walewski, Ka Lung Wu, Hilde Maria Demuynck, Rob Fijnheer, Jacob H. Christensen, Milada Jankovská, MD, Pär L. Josefsson, Hanneke Kluin-Nelemans, Jose Mario Mariz, MD, Mats A. Merup, Thomas Noesslinger, Eric Van Den Neste, Josée M Zijlstra, MD, Georg Hopfinger, MD, VIT Prochazka, MD, Esa Jantunen, MD PhD, Ludmila Boudova, Jose Cabecadas, Andreas Chott, Jan M.A. Delabie, MD PhD, Laurence de Leval, MD, Arjan Diepstra, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Peter Noergaard, Andreas Rosenwald, Grzegorz Rymkiewicz, Christer Sundström, Lorenz Truemper, MD, Gerald Wulf, MD, Lauren Chong, MSc, Alyssa Bouska, PhD, Lynette Smith, Christian Gisselbrecht, Marita Ziepert, PhD, Markus Loeffler, MD, Knut Liestol, Christian Steidl, MD, Randy D. Gascoyne, MD, David W. Scott, PhDMD,FRACP,FRCPA, Bettina Altmann, PhD, Javeed Iqbal, §, Wing C Chan, MD, Helle Toldbod, MS,PhD

Blood (2018) 132 (Supplement 1): 998.

https://doi.org/10.1182/blood-2018-99-110429

Published: 2018

NARROW

Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial

Unraveling the Role and Spatial Architecture of Cancer-Associated Fibroblasts in Classical Hodgkin Lymphoma

Clinical Impact of the Spatial Organization of the Immune Tumor Microenvironment in Diffuse Large B-Cell Lymphoma

Unraveling the Transcriptional Landscape of Nodular Lymphocyte-Predominant Hodgkin Lymphoma and T-Cell/Histiocyte Rich Large B-Cell Lymphoma: Impact of Tumor Microenvironment and Checkpoint Gene Expression

Distinct Genetic and Fragmentomic Signatures of Plasma Ctdna Synergize and Resolve Clinical Challenges in Patients with Large B-Cell Lymphoma

Extranodal Marginal Zone Lymphomas Show Recurrent Mutations in DNA Repair Genes, Cancer-Associated Proliferative Signaling and NOTCH1 Signaling Pathways, Regardless of Anatomic Site

Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53- wild Type Mantle Cell Lymphoma

The Composition, Cell Interaction Patterns and Prognostic Impact of the Tumor Microenvironment in Germinal Center B-Cell and Activated B-Cell-like Diffuse Large B-Cell Lymphoma

Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome

Oncogenic Mutational Disruption of KLHL6 Dimers Fuels B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma

Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study

Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma

Protein Profiling Identify Distinct Tumor-Tissue Protein Expression Pattern Specific for Relapsing Diffuse Large B-Cell Lymphoma

ALK-Negative Anaplastic Large Cell Lymphomas Encompass Distinct Subgroups Including an ALK-Positive-like Subgroup with Favorable Prognosis

Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma

The DLBCL90 Double-Hit Gene Expression Signature Is Not Associated with Inferior Survival in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma Treated with Dose-Intensive Immunochemotherapy

Molecular Background of Double Protein Expressor B-Cell Lymphomas

Molecular Profiling of Aggressive Non-Hodgkin Lymphoma - Results from a Phase 1/2 Preben Study

Tumor Microenvironment Differs between Germinal Centre B-Cell and Non-Germinal Centre B-Cell like Diffuse Large B-Cell Lymphomas and Has Subtype-Specific Prognostic Impact on Survival

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only